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a b s t r a c t
To target the HIV CD4i envelope epitope, we primed rhesus macaques with replicating Ad-rhFLSC (HIV-
1BaLgp120 linked to macaque CD4 D1 and D2), with or without Ad-SIVgag and Ad-SIVnef. Macaques were
boosted with rhFLSC protein. Memory T-cells in PBMC, bronchoalveolar lavage and rectal tissue,
antibodies with neutralizing and ADCC activity, and Env-speciﬁc secretory IgA in rectal secretions were
elicited. Although protective neutralizing antibody levels were induced, SHIVSF162P4 acquisition following
rectal challenge was not prevented. Rapid declines in serum ADCC activity, Env-speciﬁc memory B cells
in PBMC and bone marrow, and systemic and mucosal memory T cells were observed immediately post-
challenge together with delayed anamnestic responses. Innate immune signaling resulting from
persisting Ad replication and the TLR-4 booster adjuvant may have been in conﬂict and reoriented
adaptive immunity. A different adjuvant paired with replicating Ad, or a longer post-prime interval
allowing vector clearance before boosting might foster persistent T- and B-cell memory.
Published by Elsevier Inc.
Introduction
It is widely believed that an effective human immunodeﬁciency
virus (HIV) vaccine will have to elicit both T-cell and antibody
responses in order to prevent acquisition and/or control disease
progression. In view of the high mutability of HIV and its propensity
for immune escape, highly conserved regions of viral proteins,
including envelope epitopes, are likely critical in vaccine design.
While many vaccine platforms available today induce T-cell
responses and binding antibodies, a few elicit high levels of neu-
tralizing antibodies—a testament perhaps to the less than optimal
design of the immunogens used. HIV entry into a cell involves a
complex series of conformational changes (Chan and Kim, 1998;
Sodroski, 1999) initiated by the binding of Env to CD4 and expo
sure of the highly conserved co-receptor binding site. Antibody
responses to this CD4-induced (CD4i) epitope are present in
HIV-infected individuals and display broad, potent binding and
neutralization of a spectrum of HIV isolates across clades, as well as
the highly divergent HIV-2 in the presence of soluble CD4 (Decker
et al., 2005; Guan et al., 2013). For these reasons the CD4i epitope
constitutes an attractive target for vaccine development. A protein
immunogen consisting of the full-length single-chain HIV-
1BaLgp120 linked to the D1 and D2 domains of rhesus macaque
CD4 (rhFLSC) was developed (Fouts et al., 2000). Immunizationwith
this construct elicited antibodies to CD4i sites which correlated
with control of SHIVSF162P3 infection following intrarectal challenge
of rhesus macaques (DeVico et al., 2007). In spite of these promising
results, this rhFLSC immunogen has until now not been incorpo-
rated into a viral vector for further vaccine evaluation.
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We are pursuing a strategy employing mucosal priming with
replicating adenovirus type 5 host range mutant (Ad5hr)-HIV/SIV
recombinants, followed by Env protein boosts. This approach
has elicited broad cellular immune responses and functional,
envelope-speciﬁc systemic and mucosal antibodies that correlate
with protection from HIV, SIV, and SHIV challenges in chimpanzee
and rhesus macaque models (Lubeck et al., 1997; Robert-Guroff
et al., 1998; Patterson et al., 2004; Malkevitch et al., 2006; Bogers
et al., 2008; Demberg et al., 2007). In an effort to enhance the
antibody responses induced by our platform we generated an
Ad5hr-recombinant expressing the rhFLSC immunogen, and
demonstrated its immunogenicity in mice (Thomas et al., 2013).
Here we evaluated whether priming rhesus macaques with
replicating Ad-rhFLSC and boosting with rhFLSC protein would
elicit broad neutralizing antibodies in serum and cellular immu-
nity against envelope peptides in peripheral blood and at mucosal
sites. In a second experimental arm we primed with Ad5hr
recombinants encoding rhFLSC as well as SIV Gag and SIV Nef,
followed by boosting with rhFLSC protein, expecting that this
regimen would elicit broader cellular immunity and equivalent
antibody responses. We subsequently assessed protective efﬁcacy
following a simian/human immunodeﬁciency virus (SHIV) intrar-
ectal challenge. Reduced viral loads were observed in vaccinated
macaques following challenge, but in spite of elicitation of T-cell
responses and antibodies with protective neutralizing activity
levels, prevention of SHIV acquisition was not attained. Factors
potentially associated with this lack of sterilizing immunity were
subsequently explored in depth.
Results
Favorable levels of vaccine-induced neutralizing antibodies do not
prevent SHIVSF162p4 acquisition
Previously, immunization of macaques with rhFLSC elicited
antibody responses to CD4i epitopes which were associated with
control of viremia following intrarectal challenge with SHIVSF162P3
(DeVico et al., 2007). However, all vaccinated macaques became
infected and only low-level neutralizing antibodies were elicited
against this difﬁcult to neutralize virus. Three of four macaques
neutralized SHIVSF162P3 with ID50 values ranging from 12 to 80,
while the best protected macaque had no detectable neutralizing
antibody response at all (DeVico et al., 2007). Here, we designed a
study for an intrarectal challenge with SHIVSF162P4, based on the
rationale that our prime/boost approach would elicit a higher titer
antibody response with neutralizing activity against this more
easily neutralized virus, and that we would be able to determine if
rhFLSC induced antibodies would be able to prevent SHIVSF162P4
acquisition. Two weeks after the second rhFLSC boost we evalu-
ated neutralizing antibody responses generated by the vaccine
regimen. Neutralizing antibody responses with mean titers ran-
ging from 22 to 50 were observed against tier 2 viruses of HIV
clades B and D (data not shown). Mean neutralizing antibody titers
induced against SHIVBALP4, representative of the gp120 portion of
the rhFLSC construct, were low (74 and 89 for groups 1 and 2,
respectively), whereas intermediate titers were elicited against the
SHIVSF162P4 challenge virus (253 and 266 for groups 1 and 2,
respectively; Table 1). Notably, however, these SHIVSF162P4 neu-
tralizing antibody titers were at protective levels. Bogers et al.
previously reported that vaccine-induced protection against
SHIVSF162P4 acquisition was correlated with neutralizing antibody
titer. The ﬁve protected macaques in that study had titers as low as
1:80 at the time of challenge (Bogers et al., 2008). Moreover, the
intrarectal challenge dose in that study was 1800 TCID50, which
was higher than the 256 TCID50 dose used here. We also observed
neutralizing antibodies against HIV-2 in the presence of CD4, with
mean titers of 1247 and 2654 (Table 1), comparable to those
observed (ranging from 300 to 2000) following vaccination with
rhFLSC alone (DeVico et al., 2007), and indicating that neutralizing
antibodies to the CD4i epitope were induced.
In spite of induction of promising levels of neutralizing anti-
bodies, protection against SHIVSF162P4 acquisition was not obtained
(Fig. 1). All macaques became infected following the moderate
single dose intrarectal challenge. A modest but signiﬁcant reduc-
tion in area under the curve (AUC) compared to the controls was
observed for group 2 macaques primed with Ad5hr-rhFLSC in
addition to Ad5hr-SIVgag and Ad5hr-SIVnef (p¼0.029) but not for
group 1, suggesting a beneﬁt derived by the addition of SIV Gag
and Nef recombinants. However, there was no difference in AUC
values between groups 1 and 2, allowing us to combine the
groups. The greater statistical power achieved resulted in a
signiﬁcant difference between both vaccinated groups and the
controls (p¼0.043).
Vaccine-elicited binding and neutralizing antibodies
To understand the basis for the lack of protection against acquisi-
tion, we ﬁrst evaluated humoral immune responses over the course of
the immunization and challenge. High-titered binding antibodies to
both rhFLSC and HIVBAL gp120 (titers of 106 and 105, respectively)
were elicited following the second Env administration for both vaccine
groups (Fig. 2). However, the titers were not well-sustained bet
ween immunizations. Moreover, the anamnestic response following
SHIVSF162P4 challenge appeared to be delayed. This is illustrated in
Table 2 where binding titers 2 weeks post-challenge (week 44) against
both rhFLSC and HIVBaL gp120 remain below the peak titers achieved
2 weeks post-boost (week 38) in both immunization groups. Binding
titers to rhFLSC increased by 4 weeks post-challenge (week 46),
although HIVBaL gp120-speciﬁc binding titers remained below peak
levels. We contrast this with previous studies using similar prime/
boost vaccine regimens in which signiﬁcant protective efﬁcacy was
achieved. For example, in the study by Patterson et al. (2004),
immunized with Ad-SIV and boosted with SIV Env protein by a
similar schedule to the study here prior to intrarectal SIV challenge, a
3-fold increase in binding titer to SIV gp120 was observed 2 weeks
post-challenge, with a further increase to 9-fold at 4 weeks post-
challenge. Further, in the study by Demberg et al. (2007), immunized
with Ad-HIV and boosted with HIV Env protein by the same schedule
but challenged at week 50 with SHIV89.6P, the binding antibody titer
measured at 2 weeks post-challenge was equivalent to the week 38
binding titer (Table 2), reﬂecting the longer time period between
immunization and challenge. However, by 4 weeks post-challenge the
binding titer to SHIV89.6P gp120 had increased 10-fold over the peak
pre-challenge titer. From these comparisons we conclude that here
the humoral anamnestic response to SHIVSF162P4 exposure was sig-
niﬁcantly delayed.
A similar result was obtained upon analysis of neutralizing anti-
body titers over time (Fig. 3A–C). The proﬁles of neutralizing titers
against SHIVBalp4, SHIVSF162P4, and HIV-2þsCD4 were similar for
groups 1 and 2 from 2 weeks after the second boost (week 38) out
Table 1
Neutralizing antibody titers pre-challenge (week 38).
Immunization groups ID50
SHIVBALP4 SHIVSF162P4 HIV-2þsCD4
Group 1 74715 253763 12477310
Group 2 89719 266759 265471024
Groups 3þ4 070 070 070
Data expressed as means7SEM. Week 38¼2 weeks post-boost.
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Fig. 1. Plasma viral loads following SHIVSF162P4 intrarectal challenge. Viral loads of individual macaques (panels A–C) and geometric mean viral loads of each immunization group
are shown. (A) Group 1 macaques primed with Ad5rh-FLSC and boosted with rhFLSC protein; (B) Group 2 macaques primed with Ad5rh-FLSC, Ad5hr-SIV239gag, and Ad5hr-
SIV239nefΔ1–13, and boosted with rhFLSC protein; and (C) Control macaques primed with empty Ad5hr-vector and boosted with adjuvant only (n¼4) or unimmunized (n¼4).
Fig. 2. Vaccine-induced antibody responses in serum. Geometric mean serum binding antibody titers against rhFLSC and HIVBaL gp120 over time. The arrows indicate the
time of SHIVSF162p4 challenge.
Table 2
Delayed anamnestic response in vaccinated macaques.
Macaque group Test
antigen
Geometric mean binding titer Fold increase (geometric mean)
2 weeks post-
boost
2 weeks post-
challenge
4 weeks post-
challenge
2 weeks post-challenge/2 weeks
post-boost
4 weeks post-challenge/2 weeks
post-boost
Group 1 rhFLSC 1,222,405 843,217 4,711,167 0.80 3.85
Group 2 rhFLSC 1,138,732 477,305 5,642,405 0.45 5.22
Groups 1 and 2 rhFLSC 1,179,827 646,555 5,222,660 0.58 4.54
Group 1 BaL gp120 163,052 24,335 94,192 0.13 0.54
Group 2 BaL gp120 177,372 16,101 78,199 0.09 0.44
Groups 1 and 2 BaL gp120 170,062 19,794 85,293 0.11 0.49
Patterson et al.
(2004)
SIV gp120 116,604 395,255 980,155 3.43 8.77
Demberg et al.
(2007)
SHIV89.6P
gp120
27,149 25600 289,631 0.94 10.67
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to 8 weeks post-challenge (week 50). However in all cases, neutraliz-
ing titers were lower at week 44, 2 weeks post-challenge, compared
to the week 38 titers. This is illustrated in the right-hand panels of
Fig. 3A–C, where highly signiﬁcant differences in titers between the
pre-and post-challenge time points were obtained for groups 1 and
2 macaques combined. Increases in neutralizing antibody titers only
became apparent at week 46, 4 weeks post-challenge, again reﬂecting
a delayed anamnestic response.
Env-speciﬁc memory B-cell responses
The observed delay in humoral anamnestic responses prompted us
to examine induction of Env-speciﬁc memory B cells and PB/PC. The
presence of memory B cells would indicate a readiness to rapidly
respond to viral Env, whereas the presence of PB/PC (not distinguished
by the ELISPOT assay) would indicate the presence of short-lived ASC
and/or the ability to maintain a sustained antibody response. PB/PC
levels were evaluated by ELISpot for detection of rhFLSC antibody
secreting cells (ASC) on unstimulated lymphocytes of PBMC and bone
marrow. Both rhFLSC-speciﬁc IgG and IgA ASC were absent in PBMC
prior to challenge at week 42 (Fig. 4A); however low levels of both
were seen in bone marrow at week 38 after the second Env booster
immunization and prior to challenge (Fig. 4B). The levels of these PB/
PC were similar between animals of groups 1 and 2. In contrast, both
rhFLSC-speciﬁc IgG and IgA memory B cells were readily observed by
ELISpot in lymphocytes of PBMC and bone marrow after three days of
polyclonal stimulation, initially appearing after the ﬁrst Env boost
(week 27). Notably, however, the levels of rhFLSC-speciﬁc IgGmemory
B cells declined dramatically after the SHIV challenge by week 50
(8 weeks post-challenge) in both PBMC and bone marrow (Fig. 4A
and B). A decline in rhFLSC-speciﬁc IgA ASC was less apparent.
Because of the similarities of groups 1 and 2 in levels of memory
ASC and in their proﬁles over the course of immunization, we
combined the groups for statistical analysis. As indicated by the plots
in the far right column of Fig. 4, highly signiﬁcant reductions in
rhFLSC-speciﬁc IgG memory B cell levels in PBMC and bone marrow
were observed between pre- (week 38) and post-challenge (week 50)
time points (po0.0001 and po0.0042, respectively). It is possible
that the reductions in Env-speciﬁc IgG memory B cells are in part due
to maturation into PB/PC, which were seen to increase over the 38–50
week time period (Fig. 4). However, the memory B cell reductions
seen here were unusual, as previously we had observed increases in
memory B cells in vaccinated macaques (Brocca-Cofano et al., 2011;
Demberg et al., 2013) as well as PB/PC (Demberg et al., 2013) when
levels post-challenge were compared to those observed 2 weeks post-
Env boosting. Signiﬁcant differences in rhFLSC-speciﬁc IgA memory B
cell levels over the same time period were not observed here.
Env-speciﬁc T-cell immune responses
It has long been established that viral-speciﬁc cellular immunity
can control disease progression in SIV-infected macaques (Schmitz
et al., 1999; Jin et al., 1999). More recently this has been dramatically
extended to preclinical studies in macaques where vaccine-elicited
cellular responses have led to strong control of viremia (Hansen et al.,
2011; Mudd et al., 2012; Hansen et al., 2013). Previously, our
replicating Ad-recombinant prime/protein boost strategy yielded
viral-speciﬁc T-cell responses that correlated with control of set-
point viremia (Patterson et al., 2004). Therefore we evaluated T-cell
responses elicited by the rhFLSC regimen by intracellular cytokine
staining for IFN-γ, IL-2, and TNFα in PBMC, BAL and rectal cells in
response to stimulation with Nef, Gag or Env peptides. Robust Gag-
and modest Nef-speciﬁc CD4 and CD8 responses, both effector
memory (EM) and central memory (CM), appeared immediately after
the ﬁrst Ad-recombinant prime in PBMC of Group 2 macaques and
were maintained throughout the course of immunization and sub-
sequent challenge period (Fig. 5A). Similar proﬁles were observed for
Gag-speciﬁc CD4EM and CD8EM cells of BAL and rectal tissue (Fig. 5B
and C), where due to insufﬁcient cells, Nef-speciﬁc responses were not
assayed. Env-speciﬁc CD4 and CD8 responses developed more slowly
and were observed at lower levels compared to Gag-speciﬁc res-
ponses in PBMC as well as BAL and rectal tissue (Fig. 5A–C). The low
level cellular responses seen at week 14 after the two Ad-recombinant
immunizations actually declined signiﬁcantly with the ﬁrst rhFLSC
boost (week 27) in the CD8CM PBMC population (p¼0.0076) and in
BAL CD4EM cells (p¼0.0063). Subsequently, Env-speciﬁc responses
pre-challenge in general peaked at week 38, two weeks after the sec-
ond rhFLSC boost.
Fig. 3. Vaccine-induced serum neutralizing antibody titers. Neutralizing antibody
titers to (A) SHIVBaLp4, (B) SHIVSF162p4, and (C) HIV-2 with sCD4 added. Values
shown are log titersþSEM. The far right-hand plots contrast week 38 and 44
responses of combined groups 1 and 2 macaques. Signiﬁcant differences were
evaluated by Wilcoxon matched-pairs signed rank test following log transforma-
tion. The arrows indicate the time of SHIVSF162p4 challenge.
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Fig. 4. Vaccine-induced IgG and IgA ASC. (A) PBMC and (B) bone marrow plasma cells/plasma blasts (evaluated by ELISpot on unstimulated cells) and memory B-cells
(evaluated by ELISpot on stimulated cells as described in Materials and methods). Env-speciﬁc IgG and IgA ASC are shown as the ratio of Env-speciﬁc ASC divided by total IgG
or IgA ASC in each sample. The far right-hand plots contrast weeks 38 and 44 responses. Statistical differences were analyzed by the Wilcoxon signed rank test performed on
arcsine-transformed percentages. Arrows indicate the time of SHIVSF162p4 challenge.
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Following SHIVSF162P4 challenge at week 42, Gag-speciﬁc responses
in group 2 macaques were in general maintained, or tended to
increase. In contrast, Env-speciﬁc responses in both immunization
groups appeared to decline in most cases. Because of the similarities
in levels of Env-speciﬁc CD4 and CD8 memory responses in groups
1 and 2 we combined the groups for further analysis. As indicated by
the paired pre- (week 38) and post-challenge (week 44) responses (far
right columns, Fig. 5) CD4EM and CD4CM responses in PBMC signiﬁ-
cantly declined (Fig. 5A; p¼0.018 and p¼0.013, respectively). Similar
signiﬁcant declines in Env-speciﬁc responses over the same time
period were also seen in CD4EM and CD8EM BAL cells (Fig. 5B;
p¼0.0042 and p¼0.0063, respectively) and in CD8EM cells of the
rectum (Fig. 5C; po0.0001). A decline in rectal Env-speciﬁc CD4EM
cells only approached statistical signiﬁcance. Similar to the neutraliz-
ing antibody titers and Env-speciﬁc memory B-cell responses, Env-
speciﬁc anamnestic responses by CD4 T cells in PBMC and by both
CD4 and CD8 Tcells of rectal tissue were delayed. Nonewere observed
in CD8 T cells of PBMC or in BAL CD4 and CD8 T cells.
Fig. 5. Vaccine-induced cytokine positive cells. Intracellular cytokine staining of (A) PBMC, (B) BAL, (C) rectal tissue for speciﬁc CD4þ and CD8þ memory T cells secreting
IFN-γ, IL-2, and TNF-α. (A–C) Stacked responses to HIV Env, SIV Gag, and SIV Nef peptide pools by CD4þ and CD8þ CM and EM cells over the course of immunization. The far
right-hand plots contrast weeks 38 and 44 Env-speciﬁc cellular responses of combined groups 1 and 2 macaques. Statistical analysis was done by the Wilcoxon signed rank
test performed on arcsine-transformed percentages. The arrows indicate the time of SHIVSF162p4 challenge. Error bars represent standard errors of the mean (SEM).
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Factors inﬂuencing differences in viral load
In spite of the failure to prevent SHIV acquisition and the delay
in anamnestic responses, both humoral (Table 2, Fig. 3) and in
particular the rectal CD4 and CD8 responses (Fig. 5) may have
contributed to the reduced viral loads post-challenge. Because the
animals were rectally challenged we additionally evaluated levels
of Env-speciﬁc anti-IgA (secretary component) in rectal secretions.
Detection of Env-speciﬁc IgA using anti-secretory component is
less sensitive than using anti-IgA directly. Nevertheless, Env-
speciﬁc sIgA titers increased two to four weeks post-challenge
(Fig. 6). Thus along with other vaccine-induced humoral and
cellular responses, rectal Env-speciﬁc sIgA may also have contrib-
uted to the reduced viral loads in the immunized macaques as
shown by area-under-the-curve values (Fig. 1).
Non-neutralizing antibodies by interacting with Fc receptors
mediate a number of functional activities (Alter and Moody, 2010;
Nimmerjahn and Ravetch, 2008). These have been suggested to
inhibit the spread of HIV (Holl et al., 2006; Robinson, 2013) and
have also been implicated in the protective efﬁcacy seen in the
Phase III HIV vaccine trial, RV144 (Haynes et al., 2012). Vaccine-
elicited non-neutralizing antibodies have also been correlated
with protection against both SIV (Gomez-Roman et al., 2005)
and SHIV (Xiao et al., 2010) in rhesus macaques. To determine if
antibodies induced by the rhFLSC vaccine regimen impacted the
challenge outcome, we measured ADCC activity pre- (week 38)
and post-challenge (week 44; Fig. 7). Both groups of vaccinated
animals showed comparable ADCC titers and maximum killing
percentages at both time points (Fig. 7A, B, D, and E). The post-
immunization ADCC titers did not correlate with reduced viremia
in the vaccinated macaques (data not shown), perhaps in part due
to the fact that the activity levels were not sustained, but dropped
signiﬁcantly between weeks 38 and 44 (Fig. 7C and F). However,
by week 44 the macaques with the smallest drop in percent ADCC
killing tended to have lower peak viremia, although statistical
signiﬁcance was not reached (Fig. 7G). Nevertheless, the ADCC
activity that remained was an important factor as a signiﬁcant
negative correlation was seen between the 50% maximum killing
titer at week 44 and subsequent viral loads at week 46 (Fig. 7H).
Thus ADCC activity elicited by the rhFLSC vaccine regimen had a
measurable effect on the challenge outcome.
Discussion
In this study we evaluated a prime/boost vaccine design target-
ing CD4i epitopes, asking whether priming with a replicating
Ad-recombinant encoding rhFLSC would confer added beneﬁt to
immunizations with rhFLSC protein alone, previously shown to result
in reduced viremia levels following SHIVSF162P3 challenge (DeVico et
al., 2007). We postulated that the prime/boost regimen would elicit
both systemic and mucosal immune responses, including broad
neutralizing antibodies and Env-speciﬁc cellular immunity, and that
these responses would induce sterilizing immunity against intrar-
ectal SHIVSF162P4 challenge and/or reduce viremia. We observed
induction of speciﬁc cellular immune responses, both in blood and
BAL and in rectal tissue. Even though the neutralization breadth was
more limited than we had hoped, the vaccine regimen elicited
antibodies capable of neutralizing the challenge virus at titers
equivalent to or higher than those previously associated with
sterilizing protection following either intrarectal or intravaginal
SHIVSF162P4 challenge (Bogers et al., 2008; Barnett et al., 2008).
Env-speciﬁc secretory IgA antibodies were seen in rectal secretions,
and antibodies mediating ADCC activity, signiﬁcantly correlated with
reduced viremia, were induced. As favorable levels of systemic and
mucosal, cellular and humoral immune responses were achieved, the
challenge outcome, including lack of protection from acquisition and
only a modest reduction of viral loads in the vaccinated compared to
control macaques, was surprising. One factor perhaps contributing to
this unexpected outcome was our use of a single moderate challenge
dose, used to insure infection of all the control macaques. While
repeated low-dose challenges are more representative of natural HIV
transmission (McDermott et al., 2004) and permit one to more
effectively monitor the protective efﬁcacy of candidate vaccines, here
the number of macaques studied did not provide sufﬁcient statistical
power to make the use of this challenge method feasible.
Other factors likely impacted the challenge outcome as well. In
addition to neutralizing antibody titer, both the avidity of the
vaccine-induced antibody (Demberg et al., 2013; Barnett et al.,
2010) and a strong, rapid anamnestic response (Patterson et al.,
2004; Demberg et al., 2013; Barnett et al., 2010; Buckner et al., 2004;
Sundling et al., 2010) may be important for protective efﬁcacy.
Here we observed either delayed or absent anamnestic responses
in binding and neutralizing antibodies and in cellular immune
responses. Some decline in the measurable antibody response post-
challenge may have resulted from immune complex formation, not
evaluated here. However the decline contrasted sharply with previous
studies in which rapid increases in Env-speciﬁc antibodies were
observed following both SIV and SHIV challenges (Table 2; 9, 12).
We suggest that the delayed antibody response is most likely related
to the signiﬁcant drop in Env-speciﬁc IgG memory B cells, seen in
both peripheral blood and bone marrow following SHIV exposure
(Fig. 4A and B). Loss of memory B cells has been well documented in
both HIV (De Milito et al., 2001; Titanji et al., 2006) and SIV (Peruchon
Fig. 6. Env-speciﬁc secretory IgA in rectal secretions. Rectal swabs were collected
at 36, 44 and 46 weeks post-immunization. Time of SHIVSF162P4 challenge was
week 42, marked by the arrow. Graphs show mean secretory antibody titers7SEM.
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et al., 2009; Kuhrt et al., 2010) infection. However, as with Env-
speciﬁc antibody responses, we have previously observed signiﬁcant
increases in Env-speciﬁc memory B cells post-challenge in vaccinated
macaques (Brocca-Cofano et al., 2011; Demberg et al., 2013). Thus, it is
not known why the induction of strong Env-speciﬁc memory B cells
over the course of immunization did not offset the subsequent B-cell
dysfunction. A better elicitation of Env-speciﬁc plasma cells could
have provided more sustained antibody responses, obviating the need
for rapid antibody production bymemory B cells upon virus exposure.
It is possible that the SHIVSF162P4 envelope expressed post-challenge
inhibited proliferation and expansion of the memory B cell subset by
inducing TGF-(1 production and expression of the B cell inhibitory
receptor, FcRL4, as recently described (Jelicic et al., 2013). This
possibility should be explored. The observed loss of CD4EM and CD4CM
cells post-challenge (Fig. 5A and B) may also have resulted in
insufﬁcient T cell help necessary for sustaining memory B cell
expansion.
We also observed a signiﬁcant drop in CD8CM cells in peripheral
blood and in CD4EM BAL cells between the second Ad-recombinant
immunization and the ﬁrst Env boost. This result, as well as the less
than optimal induction of B cell memory, may reﬂect conﬂicts in
induced innate immune responses elicited by the Ad immunizations
and the adjuvant/protein boost. Precedence for the reorientation of
immune responses by TLR ligands has been established in allergy
research, where they have been shown to reverse Th2 skewing and
restore the Th1/Th2 balance (Kanzler et al., 2007). This shift derives
from the dependence of Th1 and Th2 cell differentiation on their
cytokine environment. IFN-γ and IL-12 are the dominant factors for
development of Th1 cells, while the presence of IL-4 leads to Th2
cells (Seder and Paul, 1994). These cytokines, also produced by Th1
Fig. 7. Serum antibodies mediating ADCC pre- and post-challenge. Serum samples collected at (A, D) week 38 and (B, E) week 44 (2 weeks post-challenge) were evaluated
for ADCC activity. (C) Plots contrasting weeks 38 and 44 ADCC titers and (F) percent maximum killing responses of combined groups 1 and 2 macaques. (G) Week 44 percent
maximum killing values were subtracted from those at week 38 and the resulting difference was plotted against peak viral loads. (H) Signiﬁcant negative correlation of ADCC
50% maximum killing titers at week 44 with viral loads at week 46. Titers less than background were assigned values of 10. Statistical analyses were done by (A, B, D, E) the
Mann–Whitney–Wilcoxon test, (C, F) the Wilcoxon signed rank test or (G, H) Spearman's rank correlation.
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and Th2 cells respectively, are cross-regulatory, so that IL-4
diminishes priming by IFN-γ and IFN-γ diminishes priming by IL-4.
Thus, TLR agonists as adjuvants, by interacting with TLR on a variety
of cell types and triggering production of different cytokines, can
have potent effects on T-helper cell induction, leading to modulation
of immune responses. These effects are not always predictable. For
example, a TLR4 agonist, as contained here in the EM005 adjuvant
(Coler et al., 2011), is expected to promote Th1 responses, yet it has
recently been shown that TLR-4 stimulation of human basophils
leads to IL-4 production. In fact in the presence of IgE, such
stimulation can result in Th2 skewing (Suurmond et al., 2014).
Innate immune responses to Ad are mediated by numerous
signaling pathways, including not only multiple MyD88-dependent
TLR signaling pathways (Rhee et al., 2011) but also lectin receptors,
inﬂammasome signaling comprising AIMs-like receptors, NOD-like
receptors and RIG-1-like receptors (Hendrickx et al., 2014). Moreover,
Ad, either because of immune-stimulatory effects of the viral
structural antigens or other gene products, itself acts as a potent
adjuvant (Molinier-Frenkel et al., 2002; Gibson et al., 1982). Further,
we have shown that replication-competent Ad is broadly distributed
in macaque tissues, and following mucosal immunization targets
macrophages and mDC in BAL and rectal mucosa. It can persist at
least 25 weeks in rectal tissue (Patterson et al., 2012). Therefore we
cannot exclude that residual adenovirus may have still been present
at the time of the Env booster immunizations, leading to combined
effects of the Ad recombinants together with the administered
adjuvant. Moreover, it has been shown that adjuvants differ in their
effects depending on the length of time following administration,
such that short-term effects might differ from long-term effects
(Morrow et al., 2010). A thorough analysis of cytokine responses over
the course of replicating Ad priming and Env/adjuvant boosting
would be extremely valuable in addressing these issues.
The EM-005 adjuvant used here contains GLA, a synthetic lipid A
derivative and TLR-4 agonist (Coler et al., 2011). Pattern recognition
receptors (PRR) can induce a variety of responses depending on the
cell type activated, the ligand recognized, and the history of the
responding cell (Schenten and Medzhitov, 2011). Pairing of the
replicating Ad-recombinant with the TLR-4 agonist may not have
provided the optimal outcome: maintenance and boosting of cellular
memory while inducing a potent anti-Env antibody response. The
latter may have beneﬁtted from a TLR2 agonist, shown to induce anti-
Ad neutralizing antibody and anti-transgene responses (Appledorn
et al., 2008) following Ad vector administration.
The yellow fever vaccine, one of the most successful, has been
reported to elicit a spectrum of innate and adaptive immune
responses including a mixed Th1/Th2 cytokine proﬁle (Querec
et al., 2006). The authors indicate the importance of deﬁning
speciﬁc pattern recognition receptors that promote such a Th1/Th2
balance and elicit both long-lived neutralizing antibody and
memory T cells. Thus, further investigations to deﬁne a different
pairing of adjuvant with the replicating Ad vector are warranted.
Alternatively, a longer interval between the Ad-recombinant
priming and Env boost, which could allow clearing of the vector,
might lead to enhanced memory responses following a subse-
quent Env-EM-005 booster immunization.
As conﬁrmed here, CD4i epitopes elicit antibodies with neu-
tralizing activity (Decker et al., 2005; DeVico et al., 2007; Dey et al.,
2012) and effector functions (Guan et al., 2013) and contribute to
control of HIV infection, indicating their continued value in
vaccine design. Nevertheless, further investigation of approaches
able to enhance vaccine-elicited T- and B-cell memory and avoid
B-cell dysfunction following viral exposure is of critical impor-
tance. The choice of a replicating Ad-vector for priming immune
responses was based in part on its targeting of mucosal sites, as
well as the need for persistent antigen expression. However, in
view of this persistence, exploration of effects of combined innate
signaling molecules and/or timing of immunizations and/or adju-
vant appropriateness should be explored.
Materials and methods
Immunogens
Construction of a replication-competent Ad5hr recombinant
vaccine encoding rhFLSC (MAd5rhFLSC) was previously described
(Thomas et al., 2013). The rhFLSC consists of full length single-
chain HIVBaL gp120, a ﬂexible linker, and the D1 and D2 domains of
rhesus macaque CD4 (Fouts et al., 2000). The Ad5hr-SIV239gag and
Ad5hr-SIV239nefΔ1–13 recombinants were previously described
(Zhao et al., 2003; Patterson et al., 2003).
Animals, immunization, and challenge
Twenty-four Indian rhesus macaques (Macaca mulatta), 12 male
and 12 female, were housed and maintained at Advanced BioScience
Laboratories, Inc., (ABL, Rockville, MD) according to the standards of
the American Association for Accreditation of Laboratory Animal
Care. All were negative for SIV, simian retrovirus type D and STLV.
Eight macaques per group were immunized at week 0 intranasally
and orally, and at week 12 intratracheally, with replication-com-
petent MAd5rhFLSC (group 1) or MAd5rhFLSC, Ad5hr-SIV239gag and
Ad5hr-SIV239nefΔ1–13 (Group 2) at a dose of 5108 PFU/recombi-
nant/route. Group 1 macaques additionally received empty Ad5hr
vector to make the total Ad5hr dose 1.5109 PFU. The macaques
were boosted intramuscularly at two sites with recombinant rhFLSC
protein (Profectus BioSciences, Inc., Baltimore, MD), a total of 100 mg/
macaque, in EM005 adjuvant (10 mg in 2% oil; Infectious Disease
Research Institute (IDRI) Seattle, WA) at weeks 25 and 36. Four
control macaques (Group 3) received empty Ad5hr vector (1.5109
PFU/macaque) and adjuvant alone. Four additional controls were
naïve. All macaques were challenged intrarectally at week 42 with a
moderate single dose (256 TCID50) of SHIVSF162p4.
Sample collection
Peripheral blood mononuclear cells (PBMC) obtained throughout
the immunization course and postchallenge were puriﬁed from
whole blood by Ficoll gradient centrifugation and used immediately
for intracellular cytokine staining assays. Bone marrow lymphocytes
were similarly isolated. Bronchoalveolar lavage (BAL) samples and
rectal pinch biopsies were collected and processed as previously
described (Patterson et al., 2011). Serum samples were collected,
aliquoted, and stored at 70 1C until use. Rectal secretions were
collected as described previously (Xiao et al., 2010), and stored at
70 1C until analyzed.
Intracellular cytokine staining
Freshly isolated PBMC (2106) were stimulated with pools of
HIVBaL gp120, SIVmac239 Gag, or SIV Nef peptides and stained as
described previously (Xiao et al., 2012) except ﬂourochromes for CD4
and gamma interferon (IFN-γ) antibodies were changed to CD4-FITC
and IFN-γ-PE (both BD Biosciences). A singlet, followed by live/dead
and then lymphocytic gates, was ﬁrst applied. CD3þ T cells were
divided into CD4þ and CD8þ populations, and each population was
further subdivided into CD28þ CD95þ central memory (CM) and
CD28 CD95þ effector memory (EM) cells. The percentage of
cytokine-secreting cells in each memory cell subset was then
determined following subtraction of the values obtained with non-
stimulated samples. Data were analyzed using FlowJo software
(TreeStar Inc.).
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Binding, and neutralizing antibodies
Serum binding antibodies to rhFLSC and HIVBaL gp120 Env
protein were assessed by enzyme-linked immunosorbent assay
(ELISA) as described previously (Demberg et al., 2012). The antibody
titer was deﬁned as the reciprocal of the serum dilution at which
the optical density (OD) of the test serum was two times greater
than that of the negative-control serum diluted 1:50.
Neutralizing antibody titers against SHIVBaL-P4, SHIVSF162P3, and
SHIVSF162P4 (all grown in human PBMC) and HIV-2 7312A/V434M
(a pseudovirus produced in 293T cells) with and without sCD4
were assayed in TZM-Bl cells as described (Monteﬁori, 2004). Sera
were also evaluated for neutralization of infectious molecular
clones of tier 2 clade B and C IMC.LucR viruses (Edmonds et al.,
2010) produced in 293T cells using A3R5.7 cells (Kim et al., 2003)
as described (McLinden et al., 2013). Titers were deﬁned as the
reciprocal serum dilution at which there was a 50% reduction in
relative luminescence units compared to virus control wells which
contained no test sample.
Memory B cells, plasma blasts (PB) and plasma cells (PC)
Bone marrow and PBMC lymphocytes were isolated for enu-
meration of total and rhFLSC-speciﬁc IgG and IgA secreting B cells
as described (Brocca-Cofano et al., 2011). Brieﬂy, cells were washed
in R10 and aliquots were either assayed directly for antibody
secreting cells (ASC) by ELISPOT to quantify PB/PC, or were ﬁrst
stimulated for 3 days in R10 medium supplemented with 1 μg/ml
CpG (ODN-2006) (Operon), 0.5 μg/ml recombinant human sCD40L
(Peprotech), and 50 ng/ml recombinant human IL-21 (Peprotech)
to quantify memory B cells. Assays were carried out in duplicate,
and data are reported as the percentage of Env-speciﬁc ASC
relative to the number of total ASC.
Env-speciﬁc secretory IgA (sIgA) in mucosal samples
Rectal secretions were tested for blood contamination using
Chemstrips 5 (Boehringer Mannheim). Due to signiﬁcant amounts
of blood in the secretions which would have complicated deter-
mination of the origin of IgA and IgG antibodies present, Env-
speciﬁc sIgA in the secretions was assessed by ELISA using anti-
monkey secretory component. Brieﬂy, mucosal samples were 2-
fold serially diluted, applied to a half-area 96-well plate (Greiner
Bio-One) coated with 1 μg/ml rhFLSC, HIVBaL gp120, or SHIVSF162P3
gp120, and incubated at 4 1C overnight. HRP-conjugated goat anti-
monkey secretory component (GAMon/SC/PO; Nordic) and TMB
substrate were used in sequential steps, followed by reading the
OD at 450 nm. High-titered sera positive for reactivity against HIV
gp120 were negative in this assay at a serum dilution of 1:10.
Endpoint titers were deﬁned as the reciprocal of the sample
dilution at which the OD of the test sample was equal to twice
the mean background OD.
Antibody-dependent cell-mediated cytotoxicity (ADCC)
Serum samples collected at week 38 (2 weeks following the
second rhFLSC boost) were assessed for ADCC activity using the
RFADCC assay as previously described (Gomez-Roman et al., 2006).
Brieﬂy, rhFLSC protein was used to coat CEM.CCR5.NKr target cells
which were then co-cultured with human PBMC effectors at an E:T
ratio of 50:1. Serial dilutions of macaque sera were tested for ADCC
activity in a 4 h assay. Endpoint ADCC titers are reported as the
reciprocal serum dilution at which the background cutoff value
(mean ADCC activity over a dilution series of a pool of macaque
negative sera plus 3 standard deviations) was reached. ADCC-
mediated maximum percent killing of target cells (% ADCC Max
killing) was deﬁned for each positive sample as the highest
percent killing mediated at any of the dilutions tested. Sera with
percent killing below the cutoff value were scored negative. The
50% maximum killing titer was deﬁned as the reciprocal serum
dilution at which 50% of the ADCC maximum killing was achieved.
Quantitation of viral RNA
SHIVSF162P4 RNA in plasma was quantiﬁed by the NASBA assay
(Romano et al., 2000; Lee et al., 2010). The threshold of detection
was 50 SIV RNA copies/ml plasma.
Statistical analysis
Analyses of intracellular cytokine responses, antibody titers,
and viral loads used the exact Wilcoxon rank sum test for two-
group comparisons. The Spearman rank correlation test was used
to assess relationships between immune responses and virologic
parameters. Results of statistical analyses were considered sig-
niﬁcant at P values of r0.05.
Acknowledgments
We thank Nancy Miller (DAIDS, NIAID) and Ranajit Pal (ABL, Inc.)
for the titered SHIVSF162P4 challenge stock; Deborah Weiss,
James Treece and the animal care staff at ABL, Inc., for care of the
macaques, performance of animal procedures and collection of
tissue samples; Jamie Lee Vernon for initial setup of the ICS assay
system, Rachmat Hidajat for helpful discussion and David Liewehr
for help with the statistical analysis. This work was supported by
the Intramural Research Program of the National Institutes of
Health, National Cancer Institute.
References
Alter, G., Moody, M.A., 2010. The humoral response to HIV-1: new insights,
renewed focus. J. Infect. Dis. 202 (Suppl. 2), S315–S322.
Appledorn, D.M., Patial, S., McBride, A., Godbehere, S., Van Rooijen, N., Parameswaran,
N., Amalﬁtano, A., 2008. Adenovirus vector-induced innate inﬂammatory media-
tors, MAPK signaling, as well as adaptive immune responses are dependent upon
both TLR2 and TLR9 in vivo. J. Immunol. 181, 2134–2144.
Barnett, S.W., Srivastava, I.K., Kan, E., Zhou, F., Goodsell, A., Cristillo, A.D., Ferrai, M.G.,
Weiss, D.E., Letvin, N.L., Monteﬁori, D., Pal, R., Vajdy, M., 2008. Protection of
macaques against vaginal SHIV challenge by systemic or mucosal and systemic
vaccinations with HIV-envelope. AIDS 22, 339–348.
Barnett, S.W., Burke, B., Sun, Y., Kan, E., Legg, H., Lian, Y., Bost, K., Zhou, F., Goodsell, A.,
zur Megede, J., Polo, J., Donnelly, J., Ulmer, J., Otten, G.R., Miller, C.J., Vajdy, M.,
Srivastava, I.K., 2010. Antibody-mediated protection against mucosal simian-
human immunodeﬁciency virus challenge of macaques immunized with alpha-
virus replicon particles and boosted with trimeric envelope glycoprotein in MF59
adjuvant. J. Virol. 84, 5975–5985.
Bogers, W.M., Davis, D., Baak, I., Kan, E., Hofman, S., Sun, Y., Mortier, D., Lian, Y.,
Oostermeijer, H., Fagrouch, Z., Dubbes, R., van der Maas, M., Mooij, P., Koopman, G.,
Verschoor, E., Langedijk, J.P., Zhao, J., Brocca-Cofano, E., Robert-Guroff, M.,
Srivastava, I., Barnett, S., Heeney, J.L., 2008. Systemic neutralizing antibodies
induced by long interval mucosally primed systemically boosted immunization
correlate with protection from mucosal SHIV challenge. Virology 382, 217–225.
Brocca-Cofano, E., McKinnon, K., Demberg, T., Venzon, D., Hidajat, R., Xiao, P.,
Daltabuit-Test, M., Patterson, L.J., Robert-Guroff, M., 2011. Vaccine-elicited SIV
and HIV envelope-speciﬁc IgA and IgG memory B cells in rhesus macaque
peripheral blood correlate with functional antibody responses and reduced
viremia. Vaccine 29, 3310–3319.
Buckner, C., Gines, L.G., Saunders, C.J., Vojtech, L., Srivastava, I., Gettie, A., Bohm, R.,
Blanchard, J., Barnett, S.W., Safrit, J.T., Stamatatos, L., 2004. Priming B cell-
mediated anti-HIV envelope responses by vaccination allows for the long-term
control of infection in macaques exposed to a R5-tropic SHIV. Virology 320,
167–180.
Chan, D.C., Kim, P.S., 1998. HIV entry and its inhibition. Cell 93, 681–684.
Coler, R.N., Bertholet, S., Moutaftsi, M., Guderian, J.A., Windish, H.P., Baldwin, S.L.,
Laughlin, E.M., Duthie, M.S., Fox, C.B., Carter, D., Friede, M., Vedvick, T.S., Reed, S.G.,
2011. Development and characterization of synthetic glucopyranosyl lipid adju-
vant system as a vaccine adjuvant. PLoS One 6, e16333.
De Milito, A., Morch, C., Sonnerborg, A., Chiodi, F., 2001. Loss of memory (CD27) B
lymphocytes in HIV-1 infection. AIDS 15, 957–964.
M.A. Thomas et al. / Virology 471-473 (2014) 81–9290
DeVico, A., Fouts, T., Lewis, G.K., Gallo, R.C., Godfrey, K., Charurat, M., Harris, I.,
Galmin, L., Pal, R., 2007. Antibodies to CD4-induced sites in HIV gp120 correlate
with the control of SHIV challenge in macaques vaccinated with subunit
immunogens. Proc. Natl. Acad. Sci. USA 104, 17477–17482.
Decker, J.M., Bibollet-Ruche, F., Wei, X., Wang, S., Levy, D.N., Wang, W., Delaporte, E.,
Peeters, M., Derdeyn, C.A., Allen, S., Hunter, E., Saag, M.S., Hoxie, J.A., Hahn, B.H.,
Kwong, P.D., Robinson, J.E., Shaw, G.M., 2005. Antigenic conservation and
immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201,
1407–1419.
Demberg, T., Florese, R.H., Heath, M.J., Larsen, K., Kalisz, I., Kalyanaraman, V.S., Lee, E.M.,
Pal, R., Venzon, D., Grant, R., Patterson, L.J., Korioth-Schmitz, B., Buzby, A.,
Dombagoda, D., Monteﬁori, D.C., Letvin, N.L., Cafaro, A., Ensoli, B., Robert-Guroff,
M., 2007. A replication-competent adenovirus-human immunodeﬁciency virus
(Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen
elicits enhanced protective efﬁcacy against simian/human immunodeﬁciency virus
SHIV89.6P challenge in rhesus macaques. J. Virol. 81, 3414–3427.
Demberg, T., Brocca-Cofano, E., Xiao, P., Venzon, D., Vargas-Inchaustegui, D., Lee, E.M.,
Kalisz, I., Kalyanaraman, V.S., Dipasquale, J., McKinnon, K., Robert-Guroff, M., 2012.
Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow
during antiretroviral therapy and envelope boosting in simian immunodeﬁciency
virus SIVmac251-infected rhesus macaques. J. Virol. 86, 12591–12604.
Demberg, T., Brocca-Cofano, E., Kuate, S., Aladi, S., Vargas-Inchaustegui, D.A.,
Venzon, D., Kalisz, I., Kalyanaraman, V.S., Lee, E.M., Pal, R., DiPasquale, J.,
Ruprecht, R.M., Monteﬁori, D.C., Srivastava, I., Barnett, S.W., Robert-Guroff, M.,
2013. Impact of antibody quality and anamnestic response on viremia control
post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.
Virology 440, 210–221.
Dey, A.K., Burke, B., Sun, Y., Sirokman, K., Nandi, A., Hartog, K., Lian, Y., Geonnotti, A.R.,
Monteﬁori, D., Franti, M., Martin, G., Carﬁ, A., Kessler, P., Martin, L., Srivastava, I.K.,
Barnett, S.W., 2012. Elicitation of neutralizing antibodies directed against CD4-
induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope
glycoprotein. PLoS One 7, e30233.
Edmonds, T.G., Ding, H., Yuan, X., Wei, Q., Smith, K.S., Conway, J.A., Wieczorek, L.,
Brown, B., Polonis, V., West, J.T., Monteﬁori, D.C., Kappes, J.C., Ochsenbauer, C.,
2010. Replication competent molecular clones of HIV-1 expressing Renilla
luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408,
1–13.
Fouts, T.R., Tuskan, R., Godfrey, K., Reitz, M., Hone, D., Lewis, G.K., DeVico, A.L., 2000.
Expression and characterization of a single-chain polypeptide analogue of the
human immunodeﬁciency virus type 1 gp120-CD4 receptor complex. J. Virol.
74, 11427–11436.
Gibson, M., Tiensiwakul, P., Khoobyarian, N., 1982. Adenovirus ﬁber protein (FP)
functions as a mitogen and an adjuvant. Cell Immunol. 73, 397–403.
Gomez-Roman, V.R., Patterson, L.J., Venzon, D., Liewehr, D., Aldrich, K., Florese, R.,
Robert-Guroff, M., 2005. Vaccine-elicited antibodies mediate antibody-
dependent cellular cytotoxicity correlated with signiﬁcantly reduced acute
viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174,
2185–2189.
Gomez-Roman, V.R., Florese, R.H., Patterson, L.J., Peng, B., Venzon, D., Aldrich, K.,
Robert-Guroff, M., 2006. A simpliﬁed method for the rapid ﬂuorometric
assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol.
Methods 308, 53–67.
Guan, Y., Pazgier, M., Sajadi, M.M., Kamin-Lewis, R., Al-Darmarki, S., Flinko, R.,
Lovo, E., Wu, X., Robinson, J.E., Seaman, M.S., Fouts, T.R., Gallo, R.C., DeVico, A.L.,
Lewis, G.K., 2013. Diverse speciﬁcity and effector function among human
antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.
Proc. Natl. Acad. Sci. USA 110, E69–E78.
Hansen, S.G., Ford, J.C., Lewis, M.S., Ventura, A.B., Hughes, C.M., Coyne-Johnson, L.,
Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., Legasse, A.W., Chiuchiolo, M.J.,
Parks, C.L., Axthelm, M.K., Nelson, J.A., Jarvis, M.A., Piatak Jr., M., Lifson, J.D., Picker,
L.J., 2011. Profound early control of highly pathogenic SIV by an effector memory T-
cell vaccine. Nature 473, 523–527.
Hansen, S.G., Piatak Jr., M., Ventura, A.B., Hughes, C.M., Gilbride, R.M., Ford, J.C.,
Oswald, K., Shoemaker, R., Li, Y., Lewis, M.S., Gilliam, A.N., Xu, G., Whizin, N.,
Burwitz, B.J., Planer, S.L., Turner, J.M., Legasse, A.W., Axthelm, M.K., Nelson, J.A.,
Fruh, K., Sacha, J.B., Estes, J.D., Keele, B.F., Edlefsen, P.T., Lifson, J.D., Picker, L.J.,
2013. Immune clearance of highly pathogenic SIV infection. Nature 502,
100–104.
Haynes, B.F., Gilbert, P.B., McElrath, M.J., Zolla-Pazner, S., Tomaras, G.D., Alam, S.M.,
Evans, D.T., Monteﬁori, D.C., Karnasuta, C., Sutthent, R., Liao, H.-X., DeVico, A.L.,
Lewis, G.K., Williams, C., Pinter, A., Fong, Y., Janes, H., DeCamp, A., Huang, Y.,
Rao, M., Billings, E., Karasavvas, N., Robb, M.L., Ngauy, V., de Souza, M., Paris, R.,
Ferrari, G., Bailer, R.T., Soderberg, K.A., Andrews, C., Berman, P.W., Frahm, N.,
De Rosa, S.C., Alpert, M.D., Yates, N.L., Shen, X., Koup, R.A., Pitisuttithum, P.,
kaewkungwal, J., Nitayaphan, S., Rerks-Ngarm, S., Michael, N.L., Kim, J.H., 2012.
Immune-correlates analysis of an HIV-1 vaccine efﬁcacy trial. New Engl. J. Med.
366, 1275–1286.
Hendrickx, R., Stichling, N., Koelen, J., Kuryk, L., Lipieac, A., Greber, U.F., 2014. Innate
immunity to adenovirus. Hum Gene Ther. 25, 265–284.
Holl, V., Peressin, M., Decoville, T., Schmidt, S., Zolla-Pazner, S., Aubertin, A.M.,
Moog, C., 2006. Nonneutralizing antibodies are able to inhibit human immu-
nodeﬁciency virus type 1 replication in macrophages and immature dendritic
cells. J. Virol. 80, 6177–6181.
Jelicic, K., Cimbro, R., Nawaz, F., Huang, D.W., Zheng, X., Yang, J., Lempiciki, R.A.,
Pascuccio, M., Van Ryk, D., Schwing, C., Hiatt, J., Okwara, N., Wei, D., Roby, G.,
David, A., Hwang, I.Y., Kehrl, J.H., Arthos, J., Cicala, C., Fauci, A.S., 2013. The HIV-1
envelope protein gp120 impairs B cell proliferation by inducing TGF-(1
production and FcRL4 expression. Nature Immunol. 14, 1256–1265.
Jin, X., Bauer, D.E., Tuttleton, S.E., Lewin, S., Gettie, A., Blanchard, J., Irwin, C.E., Safrit,
J.T., Mittler, J., Weinberger, L., Kostrikis, L.G., Zhang, L., Perelson, A.S., Ho, D.D.,
1999. Dramatic rise in plasma viremia after CD8(þ) T cell depletion in simian
immunodeﬁciency virus-infected macaques. J. Exp. Med. 189, 991–998.
Kanzler, H., Barrat, F.J., Hessel, E.M., Coffman, R.L., 2007. Therapeutic targeting of
innate immunity with Toll-like receptor agonists and antagonists. Nature Med.
13, 552–559.
Kim, J.H., Pitisuttithum, P., Kamboonruang, C., Chuenchitra, T., Mascola, J., Frankel, S.S.,
DeSouza, M.S., Polonis, V., McLinden, R., Sambor, A., Brown, A.E., Phonrat, B.,
Rungruengthanakit, K., Duliege, A.M., Robb, M.L., McNeil, J., Birx, D.L., Thai AIDS
Vaccine Evaluation Group, 2003. Speciﬁc antibody responses to vaccination with
bivalent CM235/SF2 gp120: detection of homologous and heterologous neutraliz-
ing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res. Hum. Retrovir. 19,
807–816.
Kuhrt, D., Faith, S.A., Leone, A., Rohankedkar, M., Sodora, D.L., Picker, L.J., Cole, K.S.,
2010. Evidence of early B-cell dysregulation in simian immunodeﬁciency virus
infection: rapid depletion of naïve and memory B-cell subsets with delayed
reconstitution of the naïve B-cell population. J. Virol. 84, 2466–2476.
Lee, E.M., Chung, H.K., Livesay, J., Suschak, J., Finke, L., Hudacik, L., Galmin, L.,
Bowen, B., Markham, P., Cristillo, A., Pal, R., 2010. Molecular methods for
evaluation of virological status of nonhuman primates challenged with simian
immunodeﬁciency or simian-human immunodeﬁciency viruses. J. Virol. Meth-
ods 163, 287–9428.
Lubeck, M.D., Natuk, R., Myagkikh, M., Kalyan, N., Aldrich, K., Sinangil, F., Alipanah, S.,
Murthy, S.C., Chanda, P.K., Nigida Jr., S.M., Markham, P.D., Zolla-Pazner, S., Steimer, K.,
Wade, M., Reitz Jr., M.S., Arthur, L.O., Mizutani, S., Davis, A., Hung, P.P., Gallo, R.C.,
Eichberg, J., Robert-Guroff, M., 1997. Long-term protection of chimpanzees against
high-dose HIV-1 challenge induced by immunization. Nat. Med. 3, 651–658.
Malkevitch, N.V., Patterson, L.J., Aldrich, M.K., Wu, Y., Venzon, D., Florese, R.H.,
Kalyanaraman, V.S., Pal, R., Lee, E.M., Zhao, J., Cristillo, A., Robert-Guroff, M.,
2006. Durable protection of rhesus macaques immunized with a replicating
adenovirus-SIV multigene prime/protein boost vaccine regimen against a
second SIVmac251 rectal challenge: role of SIV-speciﬁc CD8þ T cell responses.
Virology 353, 83–98.
McDermott, A.B., Mitchen, J., Piaskowski, S., De Souza, I., Yant, L.J., Stephany, J.,
Furlott, J., Watkins, D.I., 2004. Repeated low-dose mucosal simian immunode-
ﬁciency virus SIVmac239 challenge results in the same viral and immunological
kinetics as high-dose challenge: a model for the evaluation of vaccine efﬁcacy
in nonhuman primates. J. Virol. 78, 3140–3144.
McLinden, R.J., Labranche, C.C., Chenine, A.L., Polonis, V.R., Eller, M.A., Wieczorek, L.,
Ochsenbauer, C., Kappes, J.C., Perfetto, S., Monteﬁori, D.C., Michael, N.L., Kim, J.H.,
2013. Detection of HIV-1 neutralizing antibodies in a human CD4(þ)/CXCR4
(þ)/CCR5(þ) T-lymphoblastoid cell assay system. PLoS One 8, e77756.
Molinier-Frenkel, V., Lengagne, R., Gaden, F., Hong, S.S., Choppin, J., Gahery-Segard, H.,
Boulanger, P., Guillet, J.G., 2002. Adenovirus hexon protein is a potent adjuvant for
activation of a cellular immune response. J. Virol. 76, 127–135.
Monteﬁori, D.C., 2004. Evaluating neutralizing antibodies against HIV, SIV, and
SHIV in luciferase reporter gene assays. Curr. Prot. Immunol. 64,
12.11.1–12.11.17.
Morrow, M.P., Yan, J., Pankhong, P., Ferraro, B., Lewis, M.G., Khan, A.S., Sardesai, N.Y.,
Weiner, D.B., 2010. Unique Th1/Th2 phenotypes induced during priming and
memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in
rhesus macaques. Clin. Vac. Immunol. 17, 1493–1499.
Mudd, P.A., Martins, M.A., Ericsen, A.J., Tully, D.C., Power, K.A., Bean, A.T.,
Piaskowski, S.M., Duan, L., Seese, A., Gladden, A.D., Weisgrau, K.L., Furlott, J.R.,
Kim, Y.I., Veloso de Santana, M.G., Rakasz, E., Capuano 3rd, S., Wilson, N.A.,
Bonaldo, M.C., Galler, R., Allison, D.B., Piatak Jr., M., Haase, A.T., Lifson, J.D.,
Allen, T.M., Watkins, D.I., 2012. Vaccine-induced CD8þ T cells control AIDS
virus replication. Nature 491, 129–133.
Nimmerjahn, F., Ravetch, J.V., 2008. Fcgamma receptors as regulators of immune
responses. Nat. Rev. Immunol. 8, 34–47.
Patterson, L.J., Malkevitch, N., Pinczewski, J., Venzon, D., Lou, Y., Peng, B., Munch, C.,
Leonard, M., Richardson, E., Aldrich, K., Kalyanaraman, V.S., Pavlakis, G.N.,
Robert-Guroff, M., 2003. Potent, persistent induction and modulation of cellular
immune responses in rhesus macaques primed with Ad5hr-simian immuno-
deﬁciency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV
gp120. J. Virol. 77, 8607–8620.
Patterson, L.J., Malkevitch, N., Venzon, D., Pinczewski, J., Gomez-Roman, V.R.,
Wang, L., Kalyanaraman, V.S., Markham, P.D., Robey, F.A., Robert-Guroff, M.,
2004. Protection against mucosal simian immunodeﬁciency virus SIV(mac251)
challenge by using replicating adenovirus-SIV multigene vaccine priming and
subunit boosting. J. Virol. 78, 2212–2221.
Patterson, L.J., Daltabuit-Test, M., Xiao, P., Zhao, J., Hu, W., Wille-Reece, U.,
Brocca-Cofano, E., Kalyanaraman, V.S., Kalisz, I., Whitney, S., Lee, E.M., Pal, R.,
Monteﬁori, D.C., Dandekar, S., Seder, R., Roederer, M., Wiseman, R.W., Hirsch, V.,
Robert-Guroff, M., 2011. Rapid SIV Env-speciﬁc mucosal and serum antibody
induction augments cellular immunity in protecting immunized, elite-
controller macaques against high dose heterologous SIV challenge. Virology
411, 87–102.
Patterson, L.J., Kuate, S., Daltabuit-Test, M., Li, Q., Xiao, P., McKinnon, K., DiPasquale, J.,
Cristillo, A., Venzon, D., Haase, A., Robert-Guroff, M., 2012. Replicating adenovirus-
simian immunodeﬁciency virus (SIV) vectors efﬁciently prime SIV-speciﬁc sys-
temic and mucosal immune responses by targeting myeloid dendritic cells and
M.A. Thomas et al. / Virology 471-473 (2014) 81–92 91
persisting in rectal macrophages, regardless of immunization route. Clin. Vaccine
Immunol. 19, 629–637.
Peruchon, S., Chaoul, N., Burelout, C., Delache, B., Brochard, P., Laurent, P., Cognasse, F.,
Prevot, S., Garraud, O., Le Grand, R., Richard, Y., 2009. Tissue-speciﬁc B-cell
dysfunction and generalized memory B-cell loss during acute SIV infection. PLoS
One 4, e5966.
Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S.,
Ahmed, R., Pulendran, B., 2006. Yellow fever vaccine YF-17D activates multiple
dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J.
Exp. Med. 203, 413–424.
Rhee, E.G., Blattman, J.N., Kasturi, S.P., Kelley, R.P., Kaufman, D.R., Lynch, D.M.,
La Porte, A., Simmons, N.L., Clark, S.L., Pulendran, B., Greenberg, P.D., Barouch, D.
H., 2011. Multiple innate immune pathways contribute to the immunogenicity
of recombinant adenovirus vaccine vectors. J. Virol. 85, 315–323.
Robert-Guroff, M., Kaur, H., Patterson, L.J., Leno, M., Conley, A.J., McKenna, P.M.,
Markham, P.D., Richardson, E., Aldrich, K., Arora, K., Murty, L., Carter, L., Zolla-
Pazner, S., Sinangil, F., 1998. Vaccine protection against a heterologous, non-
syncytium-inducing, primary human immunodeﬁciency virus. J. Virol. 72,
10275–10280.
Robinson, H.L., 2013. Non-neutralizing antibodies in prevention of HIV infection.
Expert Opin. Biol. Ther. 13, 197–207.
Romano, J.W., Shurtliff, R.N., Dobratz, E., Gibson, A., Hickman, K., Markham, P.D., Pal, R.,
2000. Quantitative evaluation of simian immunodeﬁciency virus infection using
NASBA technology. J. Virol. Methods 86, 61–70.
Schenten, D., Medzhitov, R., 2011. The control of adaptive immune responses by the
innate immune system. Adv. Immunol. 109, 87–124.
Schmitz, J.E., Kuroda, M.J., Santra, S., Sasseville, V.G., Simon, M.A., Lifton, M.A.,
Racz, P., Tenner-Racz, K., Dalesandro, M., Scallon, B.J., Ghrayeb, J., Forman, M.A.,
Monteﬁori, D.C., Rieber, E.P., Letvin, N.L., Reimann, K.A., 1999. Control of viremia
in simian immunodeﬁciency virus infection by CD8þ lymphocytes. Science
283, 857–860.
Seder, R.A., Paul, W.E., 1994. Acquisition of lymphokine-producing phenotype by
CD4þ T cells. Annu. Rev. Immunol. 12, 635–673.
Sodroski, J.G., 1999. HIV-1 entry inhibitors in the side pocket. Cell 99, 243–246.
Sundling, C., O'Dell, S., Douagi, I., Forsell, M.N., Morner, A., Lore, K., Mascola, J.R.,
Wyatt, R.T., Hedestam, G.B.K., 2010. Immunization with wild-type or CD4-
binding-defective HIV-1 Env trimers reduces viremia equivalently following
heterologous challenge with simian-human immunodeﬁciency virus. J. Virol.
84, 9086–9095.
Suurmond, J., Stoop, J.N., Rivellese, F., Bakker, A.M., Huizinga, T.W.J., Toes, R.E.M.,
2014. Activation of human basophils by combined toll-like receptor- and FcεRI-
triggering can promote Th2 skewing of naïve T helper cells. Eur. J. Immunol. 44,
386–396.
Thomas, M.A., Song, R., Demberg, T., Vargas-Inchaustegui, D.A., Venzon, D.,
Robert-Guroff, M., 2013. Effects of the deletion of early region 4 (E4) open
reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction,
transgene expression, and immunogenicity of replicating adenovirus HIV
vaccine vectors. PLoS One 8, e76344.
Titanji, K., De Milito, A., Cagigi, A., Thorstensson, R., Grutzmeier, S., Atlas, A.,
Hejdeman, B., Kroon, F.P., Lopalco, L., Nilsson, A., Chiodi, F., 2006. Loss of
memory B cells impairs maintenance of long-term serologic memory during
HIV-1 infection. Blood 108, 1580–1587.
Xiao, P., Zhao, J., Patterson, L.J., Brocca-Cofano, E., Venzon, D., Kozlowski, P.A.,
Hidajat, R., Demberg, T., Robert-Guroff, M., 2010. Multiple vaccine-elicited
nonneutralizing antienvelope antibody activities contribute to protective efﬁ-
cacy by reducing both acute and chronic viremia following simian/human
immunodeﬁciency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 84,
7161–7173.
Xiao, P., Patterson, L.J., Kuate, S., Brocca-Cofano, E., Thomas, M.A., Venzon, D.,
Zhao, J., DiPasquale, J., Fenizia, C., Lee, E.M., Kalisz, I., Kalyanaraman, V.S., Pal, R.,
Monteﬁori, D., Keele, B.F., Robert-Guroff, M., 2012. Replicating adenovirus-
simian immunodeﬁciency virus (SIV) recombinant priming and envelope
protein boosting elicits localized, mucosal IgA immunity in rhesus macaques
correlated with delayed acquisition following a repeated low-dose rectal SIV
(mac251) challenge. J. Virol. 86, 4644–4657.
Zhao, J., Lou, Y., Pinczewski, J., Malkevitch, N., Aldrich, K., Kalyanaraman, V.S., Venzon,
D., Peng, B., Patterson, L.J., Edghill-Smith, Y., Woodward, R., Pavlakis, G.N., Robert-
Guroff, M., 2003. Boosting of SIV-speciﬁc immune responses in rhesus macaques
by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombi-
nants. Vaccine 21, 4022–4035.
M.A. Thomas et al. / Virology 471-473 (2014) 81–9292
